ADBiotech (A179530) 주식 개요에이디바이오텍은 가축, 수산, 인체용 항체를 개발하여 국내 및 해외에 판매하고 있습니다. 자세히 보기A179530 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성4/6배당0/6위험 분석지난 1년 동안 주주가 크게 희석되었습니다.지난 5년간 매년 수익이 24.5% 감소했습니다.지난 3개월 동안 주가 변동성이 KR 시장과 비교했을 때 매우 높았습니다.의미 있는 시가총액이 없습니다(₩52B)모든 위험 점검 보기A179530 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩2.65k488.1% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-8b15b2016201920222025202620282031Revenue ₩14.6bEarnings ₩2.1bAdvancedSet Fair ValueView all narrativesADBiotech Co., Ltd. 경쟁사MYUNGMOON PharmLtdSymbol: KOSE:A017180Market cap: ₩50.8bJin Yang PharmaceuticalSymbol: KOSDAQ:A007370Market cap: ₩57.5bKorea Arlico PharmLtdSymbol: KOSDAQ:A260660Market cap: ₩47.9bEnzychem LifesciencesSymbol: KOSDAQ:A183490Market cap: ₩76.4b가격 이력 및 성과ADBiotech 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩2,650.0052주 최고가₩5,450.0052주 최저가₩1,300.00베타0.181개월 변동-0.93%3개월 변동70.64%1년 변동46.41%3년 변동-36.07%5년 변동-75.91%IPO 이후 변동-48.38%최근 뉴스 및 업데이트공시 • Mar 17ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South KoreaNew Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (115% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$25.5m).공시 • Nov 16ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million.ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 296,208 Price\Range: KRW 3376 Transaction Features: Subsequent Direct Listing공시 • Oct 28ADBiotech Co., Ltd. announced that it expects to receive KRW 16.569996684 billion in fundingADBiotech Co., Ltd. announced a private placement to issue 6,152,988 shares at an issue price of KRW 2,693 per share for gross proceeds of KRW 16,569,996,684 on October 27, 2025. The transaction will include participation from new investor BK Partners Investment Fund 1 3,107,259 shares and BK Partners Investment Fund 2 3,045,729 shares. The transaction has been approved by shareholders, restricted to a hold period and expected to close on December 17, 2025.공시 • Oct 21ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 346,140 Price\Range: KRW 2889 Transaction Features: Subsequent Direct ListingNew Risk • Jul 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩35.5b market cap, or US$25.8m).더 많은 업데이트 보기Recent updates공시 • Mar 17ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South KoreaNew Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (115% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$25.5m).공시 • Nov 16ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million.ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 296,208 Price\Range: KRW 3376 Transaction Features: Subsequent Direct Listing공시 • Oct 28ADBiotech Co., Ltd. announced that it expects to receive KRW 16.569996684 billion in fundingADBiotech Co., Ltd. announced a private placement to issue 6,152,988 shares at an issue price of KRW 2,693 per share for gross proceeds of KRW 16,569,996,684 on October 27, 2025. The transaction will include participation from new investor BK Partners Investment Fund 1 3,107,259 shares and BK Partners Investment Fund 2 3,045,729 shares. The transaction has been approved by shareholders, restricted to a hold period and expected to close on December 17, 2025.공시 • Oct 21ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 346,140 Price\Range: KRW 2889 Transaction Features: Subsequent Direct ListingNew Risk • Jul 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩35.5b market cap, or US$25.8m).공시 • Jun 10ADBiotech Co., Ltd. announced that it expects to receive KRW 8.285 billion in fundingADBiotech Co., Ltd. announces a private placement to issue 5,000,000 Common Shares at a price of KRW 1,657 for gross proceeds of KRW 8,285,000,000 on June 9, 2025. Expected closing date of the offering is October 31, 2025.New Risk • Jun 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩28.2b market cap, or US$20.9m).공시 • Jun 09+ 1 more updateADBiotech Co., Ltd. announced that it expects to receive KRW 5.646828991 billion in funding from OQPBIOM INC.ADBiotech Co., Ltd. announced a private placement to issue 3,407,863 common shares at an issue price of KRW 1,657 per share for gross proceeds of KRW 5,646,828,991 on June 9, 2025. The transaction will include participation from new investor OQPBIOM INC. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on August 29, 2025.New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.3b free cash flow). Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩21.0b market cap, or US$15.2m).New Risk • Apr 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩19.8b market cap, or US$13.8m).Reported Earnings • Mar 26Full year 2024 earnings released: ₩870 loss per share (vs ₩313 loss in FY 2023)Full year 2024 results: ₩870 loss per share (further deteriorated from ₩313 loss in FY 2023). Revenue: ₩11.1b (up 6.3% from FY 2023). Net loss: ₩7.95b (loss widened 178% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 49% per year whereas the company’s share price has fallen by 44% per year.New Risk • Mar 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩13.0b (US$8.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Market cap is less than US$10m (₩13.0b market cap, or US$8.92m).공시 • Mar 18ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2025ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2025, at 14:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South KoreaNew Risk • Feb 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩22.4b market cap, or US$15.5m).공시 • Dec 26ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 8.000002 billion.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 8.000002 billion. Security Name: Common Stocks Security Type: Common Stock Securities Offered: 4,026,171 Price\Range: KRW 1987분석 기사 • Dec 20Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩24.9b market cap, or US$17.3m).New Risk • Nov 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩171m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩171m free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩25.1b market cap, or US$18.0m).New Risk • Sep 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩39.1b market cap, or US$29.4m).분석 기사 • Sep 02Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Jun 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩30.1b market cap, or US$21.8m).공시 • Apr 26+ 1 more updateADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in funding from Kiwoom Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co.,LtdADBiotech Co., Ltd. announced a private placement to issue Series 6 Bearer Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 4,500,000,000 on April 25, 2024. KB Securities Co., Ltd. (In the position of fiduciary of Fund 1) for KRW 200,000,000, Mirae Asset Securities Co., Ltd. (in the fiduciary position of Fund 2) for KRW 300,000,000, KB Securities Co., Ltd. (In the position of trustee of Fund 3) for KRW 300,000,000, Samsung Securities Co., Ltd. (In the position of trustee of Fund 4) for KRW 200,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 5) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 6)) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (From the position of trustee of Fund 7) for KRW 200,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 8) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 9)) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 10) for KRW 300,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 11) for KRW 350,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 12) for KRW 700,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 13) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 14)) for KRW 500,000,000, NH Investment & Securities Co., Ltd. (From the position of trustee of Fund 15) for KRW 300,000,000, Samsung Securities Co., Ltd. (In the position of trustee of Fund 16) for KRW 150,000,000 and Kiwoom Securities Co., Ltd. for KRW 500,000,000. The transaction has been approved by the shareholders the company and is expected to close on April 26, 2024. The bonds are 100% convertible into 1,765,398 shares at a fixed conversion price of KRW 2,549 from April 26, 2025 to March 26, 2027. The bonds bear 0 coupon rate and 1% maturity rate and matures on April 26, 2029.Reported Earnings • Mar 22Full year 2023 earnings released: ₩313 loss per share (vs ₩297 profit in FY 2022)Full year 2023 results: ₩313 loss per share (down from ₩297 profit in FY 2022). Revenue: ₩10.5b (down 1.5% from FY 2022). Net loss: ₩2.86b (down 206% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩4,060, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 48% over the past three years.Valuation Update With 7 Day Price Move • Dec 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩3,320, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 49% over the past three years.New Risk • Dec 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (31% accrual ratio). Minor Risk Market cap is less than US$100m (₩32.7b market cap, or US$25.1m).Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩3,645, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 49% over the past three years.Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩104 loss per share (vs ₩29.00 loss in 3Q 2022)Third quarter 2023 results: ₩104 loss per share (further deteriorated from ₩29.00 loss in 3Q 2022). Revenue: ₩2.76b (up 48% from 3Q 2022). Net loss: ₩947.1m (loss widened 258% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 148% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩3,475, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 41% over the past three years.Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 35%After last week's 35% share price gain to ₩4,910, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 20% over the past three years.공시 • Jan 17ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion.ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion on January 13, 2023. Under the terms ADBiotech Co., Ltd. acquired 2,578,252 shares comprising of 34,451 shares of common stock and 2,543,801 shares of preferred stock. Post completion, ADBiotech Co., Ltd will own 3,528,252 shares representing 28.07% stake. The board of ADBiotech Co., Ltd. passed resolution for the transaction on January 13, 2023 and the transaction is expected to complete on January 17, 2023.공시 • May 05ADBiotech Co., Ltd. announced that it has received KRW 4.5 billion in fundingOn May 3, 2021, ADBiotech Co., Ltd. (XKON:A179530) closed the transaction.공시 • Apr 24ADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in fundingADBiotech Co., Ltd. (XKON:A179530) announced a private placement to issue series 5 registered non-guaranteed private convertible bonds for KRW 4,500,000,000 on April 22, 2021. The transaction will include participation from A-Stone Project 1 Fund for 2,500,000,000, Magna VITA Fund for KRW 700,000,000, Focus Super Rich Hedge Fund 5 for KRW 400,000,000, and other investors. The bonds carry no coupon and yield, and will mature on May 3, 2024. The bonds are 100% convertible into 170,240 common shares of the company representing 6.64% stake at the conversion price of KRW 26,433 per share. The conversion period will start from May 3, 2022 and May 2, 2024. The transaction is expected to close on May 3, 2021. The transaction has been approved by the board of directors of the company.공시 • Feb 27ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Jan 14New 90-day high: ₩26,700The company is up 48% from its price of ₩18,000 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.Is New 90 Day High Low • Dec 09New 90-day high: ₩22,950The company is up 28% from its price of ₩17,950 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Nov 13New 90-day high: ₩20,000The company is up 32% from its price of ₩15,200 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.Is New 90 Day High Low • Oct 19New 90-day high: ₩19,950The company is up 33% from its price of ₩15,000 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Is New 90 Day High Low • Sep 21New 90-day high: ₩19,000The company is up 16% from its price of ₩16,450 on 23 June 2020. The South Korean market is up 15% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 32% over the same period.공시 • Jul 18ADBiotech Co., Ltd. announced that it has received KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.On July 9, 2020, ADBiotech Co., Ltd. (XKON:A179530) closed the transaction.공시 • Jul 02ADBiotech Co., Ltd. announced that it expects to receive KRW 1 billion in fundingADBiotech Co., Ltd. (XKON:A179530) announced a private placement to issue 4th series named non-guaranteed private equity bonds for KRW 1,000,000,000 on June 30, 2020. The transaction will include participation from new investor IDV-IP Fisheries Professional Fund No. 2. The bonds bears an interest of 3% per annum and will mature on July 09, 2025. The bonds are 100% convertible into 56,179 common shares of the company representing 2.42% stake at the conversion price of KRW 17,800 per share. The conversion period will start from July 10, 2021 and ends on July 08, 2025. The subscription date for bonds is June 30, 2020 and payment date is July 09, 2020. The transaction has been approved by the board of directors of the company.공시 • Jun 30ADBiotech Co., Ltd. announced that it expects to receive KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.ADBiotech Co., Ltd. (XKON:A179530) announced a private placement of 206,897 convertible preferred shares at a price of KRW 14,500 per share for gross proceeds of KRW 3,000,006,500 on June 29, 2020. The transaction will include participation from SBI-Growth Ladder Konex Vitalization Fund No.2, a fund managed by returning investor SBI Investment Korea Co., Ltd. (KOSDAQ:A019550). The conversion period is between July 10, 2020 and July 09, 2030. The preferred shares are convertible into 206,897 common shares. The shares are redeemable. The repayment period is between July 10, 2023 and July 09, 2030.The transaction has been approved by the board of directors. The payment date is July 9, 2020.주주 수익률A179530KR PharmaceuticalsKR 시장7D2.5%2.8%10.4%1Y46.4%23.8%188.7%전체 주주 수익률 보기수익률 대 산업: A179530은 지난 1년 동안 23.8%의 수익을 기록한 KR Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: A179530은 지난 1년 동안 188.7%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A179530's price volatile compared to industry and market?A179530 volatilityA179530 Average Weekly Movement17.5%Pharmaceuticals Industry Average Movement7.2%Market Average Movement9.5%10% most volatile stocks in KR Market16.6%10% least volatile stocks in KR Market4.9%안정적인 주가: A179530의 주가는 지난 3개월 동안 KR 시장보다 변동성이 컸습니다.시간에 따른 변동성: A179530의 주간 변동성(18%)은 지난 1년 동안 안정적이었지만 KR 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트200059Hong-Gul Cheongadbiotech.com에이디바이오텍은 가축, 수산, 인체용 항체를 개발하여 국내 및 해외에 판매하고 있습니다. 항생제, 소독제, 기생충제, 일반의약품, 보조 사료, 대사성 의약품을 제공합니다. 또한 건강기능식품 및 가공식품도 제공합니다.더 보기ADBiotech Co., Ltd. 기초 지표 요약ADBiotech의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A179530 기초 통계시가총액₩52.15b순이익 (TTM)-₩3.30b매출 (TTM)₩12.90b4.0x주가매출비율(P/S)-15.8x주가수익비율(P/E)A179530는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A179530 손익계산서 (TTM)매출₩12.90b매출원가₩7.75b총이익₩5.15b기타 비용₩8.45b순이익-₩3.30b최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-167.89총이익률39.92%순이익률-25.62%부채/자본 비율109.0%A179530의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 01:12종가2026/05/27 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ADBiotech Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 17ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South Korea
New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (115% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$25.5m).
공시 • Nov 16ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million.ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 296,208 Price\Range: KRW 3376 Transaction Features: Subsequent Direct Listing
공시 • Oct 28ADBiotech Co., Ltd. announced that it expects to receive KRW 16.569996684 billion in fundingADBiotech Co., Ltd. announced a private placement to issue 6,152,988 shares at an issue price of KRW 2,693 per share for gross proceeds of KRW 16,569,996,684 on October 27, 2025. The transaction will include participation from new investor BK Partners Investment Fund 1 3,107,259 shares and BK Partners Investment Fund 2 3,045,729 shares. The transaction has been approved by shareholders, restricted to a hold period and expected to close on December 17, 2025.
공시 • Oct 21ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 346,140 Price\Range: KRW 2889 Transaction Features: Subsequent Direct Listing
New Risk • Jul 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩35.5b market cap, or US$25.8m).
공시 • Mar 17ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South Korea
New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (115% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$25.5m).
공시 • Nov 16ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million.ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 296,208 Price\Range: KRW 3376 Transaction Features: Subsequent Direct Listing
공시 • Oct 28ADBiotech Co., Ltd. announced that it expects to receive KRW 16.569996684 billion in fundingADBiotech Co., Ltd. announced a private placement to issue 6,152,988 shares at an issue price of KRW 2,693 per share for gross proceeds of KRW 16,569,996,684 on October 27, 2025. The transaction will include participation from new investor BK Partners Investment Fund 1 3,107,259 shares and BK Partners Investment Fund 2 3,045,729 shares. The transaction has been approved by shareholders, restricted to a hold period and expected to close on December 17, 2025.
공시 • Oct 21ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 346,140 Price\Range: KRW 2889 Transaction Features: Subsequent Direct Listing
New Risk • Jul 25New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩35.5b market cap, or US$25.8m).
공시 • Jun 10ADBiotech Co., Ltd. announced that it expects to receive KRW 8.285 billion in fundingADBiotech Co., Ltd. announces a private placement to issue 5,000,000 Common Shares at a price of KRW 1,657 for gross proceeds of KRW 8,285,000,000 on June 9, 2025. Expected closing date of the offering is October 31, 2025.
New Risk • Jun 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩28.2b market cap, or US$20.9m).
공시 • Jun 09+ 1 more updateADBiotech Co., Ltd. announced that it expects to receive KRW 5.646828991 billion in funding from OQPBIOM INC.ADBiotech Co., Ltd. announced a private placement to issue 3,407,863 common shares at an issue price of KRW 1,657 per share for gross proceeds of KRW 5,646,828,991 on June 9, 2025. The transaction will include participation from new investor OQPBIOM INC. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on August 29, 2025.
New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.3b free cash flow). Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩21.0b market cap, or US$15.2m).
New Risk • Apr 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩19.8b market cap, or US$13.8m).
Reported Earnings • Mar 26Full year 2024 earnings released: ₩870 loss per share (vs ₩313 loss in FY 2023)Full year 2024 results: ₩870 loss per share (further deteriorated from ₩313 loss in FY 2023). Revenue: ₩11.1b (up 6.3% from FY 2023). Net loss: ₩7.95b (loss widened 178% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 49% per year whereas the company’s share price has fallen by 44% per year.
New Risk • Mar 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩13.0b (US$8.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Market cap is less than US$10m (₩13.0b market cap, or US$8.92m).
공시 • Mar 18ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2025ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2025, at 14:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South Korea
New Risk • Feb 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩22.4b market cap, or US$15.5m).
공시 • Dec 26ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 8.000002 billion.ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 8.000002 billion. Security Name: Common Stocks Security Type: Common Stock Securities Offered: 4,026,171 Price\Range: KRW 1987
분석 기사 • Dec 20Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩24.9b market cap, or US$17.3m).
New Risk • Nov 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩171m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩171m free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩25.1b market cap, or US$18.0m).
New Risk • Sep 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩39.1b market cap, or US$29.4m).
분석 기사 • Sep 02Here's Why ADBiotech (KOSDAQ:179530) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Jun 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩30.1b market cap, or US$21.8m).
공시 • Apr 26+ 1 more updateADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in funding from Kiwoom Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co.,LtdADBiotech Co., Ltd. announced a private placement to issue Series 6 Bearer Unsecured Private Placement Convertible Bonds for the gross proceeds of KRW 4,500,000,000 on April 25, 2024. KB Securities Co., Ltd. (In the position of fiduciary of Fund 1) for KRW 200,000,000, Mirae Asset Securities Co., Ltd. (in the fiduciary position of Fund 2) for KRW 300,000,000, KB Securities Co., Ltd. (In the position of trustee of Fund 3) for KRW 300,000,000, Samsung Securities Co., Ltd. (In the position of trustee of Fund 4) for KRW 200,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 5) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 6)) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (From the position of trustee of Fund 7) for KRW 200,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 8) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 9)) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 10) for KRW 300,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 11) for KRW 350,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 12) for KRW 700,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 13) for KRW 100,000,000, NH Investment & Securities Co., Ltd. (In the position of trustee of Fund 14)) for KRW 500,000,000, NH Investment & Securities Co., Ltd. (From the position of trustee of Fund 15) for KRW 300,000,000, Samsung Securities Co., Ltd. (In the position of trustee of Fund 16) for KRW 150,000,000 and Kiwoom Securities Co., Ltd. for KRW 500,000,000. The transaction has been approved by the shareholders the company and is expected to close on April 26, 2024. The bonds are 100% convertible into 1,765,398 shares at a fixed conversion price of KRW 2,549 from April 26, 2025 to March 26, 2027. The bonds bear 0 coupon rate and 1% maturity rate and matures on April 26, 2029.
Reported Earnings • Mar 22Full year 2023 earnings released: ₩313 loss per share (vs ₩297 profit in FY 2022)Full year 2023 results: ₩313 loss per share (down from ₩297 profit in FY 2022). Revenue: ₩10.5b (down 1.5% from FY 2022). Net loss: ₩2.86b (down 206% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩4,060, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 48% over the past three years.
Valuation Update With 7 Day Price Move • Dec 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩3,320, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 49% over the past three years.
New Risk • Dec 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (31% accrual ratio). Minor Risk Market cap is less than US$100m (₩32.7b market cap, or US$25.1m).
Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩3,645, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 49% over the past three years.
Reported Earnings • Nov 19Third quarter 2023 earnings released: ₩104 loss per share (vs ₩29.00 loss in 3Q 2022)Third quarter 2023 results: ₩104 loss per share (further deteriorated from ₩29.00 loss in 3Q 2022). Revenue: ₩2.76b (up 48% from 3Q 2022). Net loss: ₩947.1m (loss widened 258% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 148% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩3,475, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 41% over the past three years.
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 35%After last week's 35% share price gain to ₩4,910, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 20% over the past three years.
공시 • Jan 17ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion.ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion on January 13, 2023. Under the terms ADBiotech Co., Ltd. acquired 2,578,252 shares comprising of 34,451 shares of common stock and 2,543,801 shares of preferred stock. Post completion, ADBiotech Co., Ltd will own 3,528,252 shares representing 28.07% stake. The board of ADBiotech Co., Ltd. passed resolution for the transaction on January 13, 2023 and the transaction is expected to complete on January 17, 2023.
공시 • May 05ADBiotech Co., Ltd. announced that it has received KRW 4.5 billion in fundingOn May 3, 2021, ADBiotech Co., Ltd. (XKON:A179530) closed the transaction.
공시 • Apr 24ADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in fundingADBiotech Co., Ltd. (XKON:A179530) announced a private placement to issue series 5 registered non-guaranteed private convertible bonds for KRW 4,500,000,000 on April 22, 2021. The transaction will include participation from A-Stone Project 1 Fund for 2,500,000,000, Magna VITA Fund for KRW 700,000,000, Focus Super Rich Hedge Fund 5 for KRW 400,000,000, and other investors. The bonds carry no coupon and yield, and will mature on May 3, 2024. The bonds are 100% convertible into 170,240 common shares of the company representing 6.64% stake at the conversion price of KRW 26,433 per share. The conversion period will start from May 3, 2022 and May 2, 2024. The transaction is expected to close on May 3, 2021. The transaction has been approved by the board of directors of the company.
공시 • Feb 27ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Jan 14New 90-day high: ₩26,700The company is up 48% from its price of ₩18,000 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period.
Is New 90 Day High Low • Dec 09New 90-day high: ₩22,950The company is up 28% from its price of ₩17,950 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Nov 13New 90-day high: ₩20,000The company is up 32% from its price of ₩15,200 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Oct 19New 90-day high: ₩19,950The company is up 33% from its price of ₩15,000 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Sep 21New 90-day high: ₩19,000The company is up 16% from its price of ₩16,450 on 23 June 2020. The South Korean market is up 15% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 32% over the same period.
공시 • Jul 18ADBiotech Co., Ltd. announced that it has received KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.On July 9, 2020, ADBiotech Co., Ltd. (XKON:A179530) closed the transaction.
공시 • Jul 02ADBiotech Co., Ltd. announced that it expects to receive KRW 1 billion in fundingADBiotech Co., Ltd. (XKON:A179530) announced a private placement to issue 4th series named non-guaranteed private equity bonds for KRW 1,000,000,000 on June 30, 2020. The transaction will include participation from new investor IDV-IP Fisheries Professional Fund No. 2. The bonds bears an interest of 3% per annum and will mature on July 09, 2025. The bonds are 100% convertible into 56,179 common shares of the company representing 2.42% stake at the conversion price of KRW 17,800 per share. The conversion period will start from July 10, 2021 and ends on July 08, 2025. The subscription date for bonds is June 30, 2020 and payment date is July 09, 2020. The transaction has been approved by the board of directors of the company.
공시 • Jun 30ADBiotech Co., Ltd. announced that it expects to receive KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd.ADBiotech Co., Ltd. (XKON:A179530) announced a private placement of 206,897 convertible preferred shares at a price of KRW 14,500 per share for gross proceeds of KRW 3,000,006,500 on June 29, 2020. The transaction will include participation from SBI-Growth Ladder Konex Vitalization Fund No.2, a fund managed by returning investor SBI Investment Korea Co., Ltd. (KOSDAQ:A019550). The conversion period is between July 10, 2020 and July 09, 2030. The preferred shares are convertible into 206,897 common shares. The shares are redeemable. The repayment period is between July 10, 2023 and July 09, 2030.The transaction has been approved by the board of directors. The payment date is July 9, 2020.
